We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+25.74%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1B
AUM Growth
-$297M
Cap. Flow
-$487M
Cap. Flow %
-48.53%
Top 10 Hldgs %
41.28%
Holding
103
New
31
Increased
13
Reduced
33
Closed
25

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$20.8M
2
TMO icon
Thermo Fisher Scientific
TMO
+$20.1M
3
GKOS icon
Glaukos
GKOS
+$19.3M
4
SYK icon
Stryker
SYK
+$18.5M
5
UNH icon
UnitedHealth
UNH
+$17.1M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$150M
2
MCK icon
McKesson
MCK
+$55.9M
3
AXSM icon
Axsome Therapeutics
AXSM
+$38.9M
4
ISRG icon
Intuitive Surgical
ISRG
+$33M
5
COR icon
Cencora
COR
+$25.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
51
Syndax Pharmaceuticals
SNDX
$1.76B
$5.1M 0.51%
242,967
-13,521
-5% -$236K
GPCR icon
52
Structure Therapeutics
GPCR
$3.74B
$4.75M 0.47%
68,248
-46,825
-41% -$1.91M
ELAN icon
53
Elanco Animal Health
ELAN
$12.1B
$4.69M 0.47%
+207,311
New +$4.51M
BTSG icon
54
BrightSpring Health Services
BTSG
$12B
$4.44M 0.44%
+118,525
New +$3.98M
RYTM icon
55
Rhythm Pharmaceuticals
RYTM
$7.72B
$4.3M 0.43%
40,210
-7,952
-17% -$844K
ABVX
56
Abivax
ABVX
$11.3B
$4.3M 0.43%
+31,878
New +$3.48M
MDGL icon
57
Madrigal Pharmaceuticals
MDGL
$11.8B
$4.23M 0.42%
+7,258
New +$3.71M
DNTH icon
58
Dianthus Therapeutics
DNTH
$6.15B
$4.1M 0.41%
99,576
+31,736
+47% +$1.23M
MOH icon
59
Molina Healthcare
MOH
$10B
$3.96M 0.39%
+22,802
New +$3.75M
CLDX icon
60
Celldex Therapeutics
CLDX
$3.26B
$3.62M 0.36%
+133,161
New +$3.51M
MDLN
61
Medline Inc
MDLN
$29.2B
$3.57M 0.36%
+85,000
New +$3.59M
ARGX icon
62
argenx
ARGX
$54.8B
$3.53M 0.35%
4,202
-2,201
-34% -$1.88M
BLTE
63
Belite Bio
BLTE
$6.44B
$3.17M 0.32%
+19,823
New +$2.35M
FTRE icon
64
Fortrea Holdings
FTRE
$1.68B
$2.85M 0.28%
+165,439
New +$2.04M
MBX
65
MBX Biosciences
MBX
$3.19B
$2.5M 0.25%
79,310
-142,195
-64% -$3.45M
CGEM icon
66
Cullinan Oncology
CGEM
$1.1B
$2.35M 0.23%
+227,003
New +$2.05M
TARS icon
67
Tarsus Pharmaceuticals
TARS
$2.85B
$2.24M 0.22%
+27,338
New +$2.04M
OM icon
68
Outset Medical
OM
$96.4M
$1.97M 0.2%
530,796
-1,199,125
-69% -$10.3M
MLYS icon
69
Mineralys Therapeutics
MLYS
$2.38B
$1.73M 0.17%
+47,637
New +$1.91M
AMLX icon
70
Amylyx Pharmaceuticals
AMLX
$2.69B
$1.63M 0.16%
134,549
-301,607
-69% -$4.1M
CRBU icon
71
Caribou Biosciences
CRBU
$163M
$1.52M 0.15%
957,787
-401,044
-30% -$842K
QURE icon
72
uniQure
QURE
$3.15B
$945K 0.09%
39,499
-6,854
-15% -$264K
TECX
73
Tectonic Therapeutic
TECX
$570M
$891K 0.09%
+42,724
New +$794K
IRON icon
74
Disc Medicine
IRON
$2.97B
$874K 0.09%
11,002
-21,537
-66% -$1.82M
RZLT icon
75
Rezolute
RZLT
$453M
$487K 0.05%
206,265
-246,468
-54% -$1.93M
1 2
3
4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
PWA
Pitcairn Wealth Advisors Conshohocken, Pennsylvania $1.09B AUM

PFM Health Sciences's Q4 2025 Portfolio in Review

As of Q4 2025, PFM Health Sciences held 103 positions worth $1B, down 23% from $1.3B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

PFM Health Sciences withdrew a net $487M in Q4 2025, closing 25 positions and reducing 33 holdings. Its most notable exit was McKesson, an estimated $55.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 88% a quarter earlier.

Against the trend, PFM Health Sciences opened a new position in Medtronic worth $20.5M.

  • PFM Health Sciences's largest Q4 2025 buy was Medtronic: 213,796 shares worth $20.5M.
  • PFM Health Sciences added most to Thermo Fisher Scientific in Q4 2025, an estimated $20.1M increase.
  • PFM Health Sciences's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $150M.
  • PFM Health Sciences fully exited McKesson in Q4 2025, selling an estimated $55.9M.
  • PFM Health Sciences's ten largest holdings make up 41% of its $1B portfolio in Q4 2025.
  • PFM Health Sciences opened 31 new positions and closed 25 in Q4 2025.
  • PFM Health Sciences's portfolio value fell 23% quarter-over-quarter to $1B.

Based on PFM Health Sciences's 13F filing for Q4 2025, filed 17 Feb 2026.